SAR and QSAR models of cyclooxygenase-1 (COX-1) inhibitors

References

• R. Garg, A. Kurup, S.B. Mekapati, and C. Hansch, Cyclooxygenase (COX) inhibitors: A comparative QSAR study, Chem. Rev. 103 (2003), pp. 703–731.
   PubMed Web of Science ®Google Scholar
• P. Vitale, A. Panella, A. Scilimati, and M.G. Perrone, COX-1 inhibitors: Beyond structure toward therapy, Med. Res. Rev. 36 (2016), pp. 641–671.
   Google Scholar
• G. Carullo, F. Galligano, and F. Aiello, Structure–activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: An overview (2009–2016), Medchemcomm 8 (2017), pp. 492–500.
   Google Scholar
• M.E. Husni, D.H. Solomon, and J.S. Coblyn, Selective COX-2 Inhibitors: Towards defining their appropriate clinical role, Clin. Rev. 9 (2002), pp. 265–268.
   Google Scholar
• J.R. Vane, Towards a better aspirin, Nature 367 (1994), pp. 215–216.
   Google Scholar
• H. Kakuta, X. Zheng, H. Oda, S. Harada, Y. Sugimoto, K. Sasaki, and A. Tai, Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor, J. Med. Chem. 51 (2008), pp. 2400–2411.
   Google Scholar
• R. Langenbach, S.G. Morham, H.F. Tiano, C.D. Loftin, B.I. Ghanayem, P.C. Chulada, J.F. Mahler, C.A. Lee, E.H. Goulding, K.D. Kluckman, H.S. Kim, and O. Smithies, Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration, Cell 83 (1995), pp. 483–492.
   Google Scholar
• A.H. Abdelazeem, M.T. El-Saadi, A.G. Safi El-Din, H.A. Omar, and S.M. El-Moghazy, Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile, Bioorg. Med. Chem. 25 (2017), pp. 665–676.
   Web of Science ®Google Scholar
• D. Picot, P.J. Loll, and R.M. Garavito, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature 367 (1994), pp. 243–249.
   Google Scholar
• M. Zhang, Z. Xia, and A. Yan, Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors, Mol. Divers. 21 (2017), pp. 235–246.
   PubMed Web of Science ®Google Scholar
• Z. Xia and A. Yan, Computational models for the classification of mPGES-1 inhibitors with fingerprint descriptors, Mol. Divers. 21 (2017), pp. 661–675.
   PubMed Web of Science ®Google Scholar
• D.H. Dawood, R.Z. Batran, T.A. Farghaly, M.A. Khedr, and M.M. Abdulla, New coumarin derivatives as potent selective COX-2 inhibitors: Synthesis, anti-inflammatory, QSAR, and molecular modeling studies, Arch. Pharm. 348 (2015), pp. 875–888.
   Google Scholar
• H.X. Liu, R.S. Zhang, X.J. Yao, M.C. Liu, Z.D. Hu, and B.T. Fan, QSAR and classification models of a novel series of COX-2 selective inhibitors: 1,5-Diarylimidazoles based on support vector machines, J. Comput. Aided Mol. Des. 18 (2004), pp. 389–399.
   Google Scholar
• S. Soltani, H. Abolhasani, A. Zarghi, and A. Jouyban, QSAR analysis of diaryl COX-2 inhibitors: Comparison of feature selection and train–test data selection methods, Eur. J. Med. Chem. 45 (2010), pp. 2753–2760.
   Google Scholar
• H.K. Jain, V.K. Mourya, and R.K. Agrawal, Inhibitory mode of 2-acetoxyphenyl alkyl sulfides against COX-1 and COX-2: QSAR analyses, Bioorg. Med. Chem. Lett. 16 (2006), pp. 5280–5284.
   PubMed Web of Science ®Google Scholar
• M.G. Perrone, P. Vitale, A. Panella, C.G. Fortuna, and A. Scilimati, General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model, Eur. J. Med. Chem. 94 (2015), pp. 252–264.
   Web of Science ®Google Scholar
• I.D. Valdes-Barrera, L.E. Cuca-Suarez, and E.D. Coy-Barrera, Nectandra amazonum-derived flavonoids as COX-1 inhibitors: In vitro and docking studies, Nat. Prod. Commun. 9 (2014), pp. 649–652.
   PubMed Web of Science ®Google Scholar
• A. Assadieskandar, A. Amirhamzeh, M. Salehi, K. Ozadali, S.N. Ostad, A. Shafiee, and M. Amini, Synthesis, cyclooxygenase inhibitory effects, and molecular modeling study of 4-aryl-5-(4-(methylsulfonyl)phenyl)-2-alkylthio and -2-alkylsulfonyl-1H-imidazole derivatives, Bioorg. Med. Chem. 21 (2013), pp. 2355–2362.
   Web of Science ®Google Scholar
• W.C. Black, C. Brideau, C.C. Chan, S. Charleson, N. Chauret, D. Claveau, D. Ethier, R. Gordon, G. Greig, J. Guay, G. Hughes, P. Jolicoeur, Y. Leblanc, D. Nicoll-Griffith, N. Ouimet, D. Riendeau, D. Visco, Z. Wang, L. Xu, and P. Prasit, 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors, J. Med. Chem. 42 (1999), pp. 1274–1281.
   Web of Science ®Google Scholar
• J. Bosch, T. Roca, J.L. Catena, O. Llorens, J.J. Perez, C. Lagunas, G. Fernandez, I. Miquel, A. Fernandez-Serrat, and C. Farrerons, Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 10 (2000), pp. 1745–1748.
   PubMed Web of Science ®Google Scholar
• D. Dubé, C. Brideau, D. Deschênes, R. Fortin, R.W. Friesen, R. Gordon, Y. Girard, D. Riendeau, C. Savoie, and C.-C. Chan, 2-Heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999), pp. 1715–1720.
   PubMed Web of Science ®Google Scholar
• S. Haider, M.S. Alam, H. Hamid, S. Shafi, A. Nargotra, P. Mahajan, S. Nazreen, A.M. Kalle, C. Kharbanda, Y. Ali, A. Alam, and A.K. Panda, Synthesis of novel triazole based benzoxazolinones: Their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation, Eur. J. Med. Chem. 70 (2013), pp. 579–588.
   Web of Science ®Google Scholar
• S. Haider, M.S. Alam, H. Hamid, S. Shafi, A. Dhulap, F. Hussain, P. Alam, S. Umar, M.A.Q. Pasha, S. Bano, S. Nazreen, Y. Ali, and C. Kharbanda, Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression, Eur. J. Med. Chem. 81 (2014), pp. 204–217.
   Web of Science ®Google Scholar
• F. Julémont, X. De Leval, C. Michaux, J.F. Renard, J.Y. Winum, J.L. Montero, J. Damas, J.M. Dogné, and B. Pirotte, Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors, J. Med. Chem. 47 (2004), pp. 6749–6759.
   Web of Science ®Google Scholar
• S.P. Khanapure, D.S. Garvey, D.V. Young, M. Ezawa, R.A. Earl, R.D. Gaston, X. Fang, M. Murty, A. Martino, M. Shumway, M. Trocha, P. Marek, S.W. Tam, D.R. Janero, and L.G. Letts, Synthesis and structure–activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors, J. Med. Chem. 46 (2003), pp. 5484–5504.
   Web of Science ®Google Scholar
• Y. Leblanc, P. Roy, S. Boyce, C. Brideau, C.C. Chan, S. Charleson, R. Gordon, E. Grimm, J. Guay, S. Léger, C.S. Li, D. Riendeau, D. Visco, Z. Wang, J. Webb, L.J. Xu, and P. Prasit, SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor, Bioorg. Med. Chem. Lett. 9 (1999), pp. 2207–2212.
   PubMed Web of Science ®Google Scholar
• C. Li, W.C. Black, C. Brideau, C.C. Chan, S. Charleson, W.A. Cromlish, D. Claveau, J.Y. Gauthier, R. Gordon, G. Greig, E. Grimm, J. Guay, K. Cheuk, D. Riendeau, M. Thrien, D.M. Visco, E. Wong, and L. Xu, A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999), pp. 3181–3186.
   PubMed Web of Science ®Google Scholar
• S.-J. Lin, W.-J. Tsai, W.-F. Chiou, T.-H. Yang, and L.-M. Yang, Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides, Bioorg. Med. Chem. 16 (2008), pp. 2697–2706.
   Google Scholar
• J.F. Renard, D. Arslan, N. Garbacki, B. Pirotte, and X. De Leval, Pyridine analogues of nimesulide: Design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors, J. Med. Chem. 52 (2009), pp. 5864–5871.
   Web of Science ®Google Scholar
• W.-J. Tsai, Y.-J. Shiao, S.-J. Lin, W.-F. Chiou, L.-C. Lin, T.-H. Yang, C.-M. Teng, T.-S. Wu, and L.-M. Yang, Selective COX-2 inhibitors. Part 1: Synthesis and biological evaluation of phenylazobenzenesulfonamides, Bioorg. Med. Chem. Lett. 16 (2006), pp. 4440–4443.
   Google Scholar
• M. Abdur Rahim, P.N. Praveen Rao, and E.E. Knaus, Isomeric acetoxy analogues of rofecoxib: A novel class of highly potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 12 (2002), pp. 2753–2756.
   PubMed Web of Science ®Google Scholar
• C. Almansa, A.F. De Arriba, F.L. Cavalcanti, L.A. Gómez, A. Miralles, M. Merlos, J. García-Rafanell, and J. Forn, Synthesis and SAR of a new series of COX-2-selective inhibitors: Pyrazolo[1,5-α]pyrimidines, J. Med. Chem. 44 (2001), pp. 350–361.
   Google Scholar
• C. Almansa, J. Alfon, A.F. de Arriba, F.L. Cavalcanti, I. Escamilla, L.A. Gomez, A. Miralles, R. Soliva, J. Bartroli, E. Carceller, M. Merlos, and J. Garcia-Rafanell, Synthesis and structure–activity relationship of a new series of COX-2 selective inhibitors: 1,5-Diarylimidazoles, J. Med. Chem. 46 (2003), pp. 3463–3475.
   Google Scholar
• S. Barbey, L. Goossens, T. Taverne, J. Cornet, V. Choesmel, C. Rouaud, G. Gimeno, S. Yannic-Arnoult, C. Michaux, C. Charlier, R. Houssin, and J.P. Hénichart, Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor, Bioorg. Med. Chem. Lett. 12 (2002), pp. 779–782.
   PubMed Web of Science ®Google Scholar
• S. Bertenshaw and J. Talley, Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors, Bioorg. Med. Chem. Lett. 6 (1996), pp. 2827–2830.
   Web of Science ®Google Scholar
• S.R. Bertenshaw, J.J. Talley, D.J. Rogier, M.I. Graneto, R.S. Rogers, W. Steven, T.D. Penning, C.M. Koboldt, A.W. Veenhuizen, Y. Zhang, and W.E. Perkins, 3,4-diarylthiophenes are selective cox-2 inhibitors, Bioorg. Med. Chem. Lett. 5 (1995), pp. 2919–2922.
   Web of Science ®Google Scholar
• P. Beswick, S. Bingham, C. Bountra, T. Brown, K. Browning, I. Campbell, I. Chessell, N. Clayton, S. Collins, J. Corfield, S. Guntrip, C. Haslam, P. Lambeth, F. Lucas, N. Mathews, G. Murkit, A. Naylor, N. Pegg, E. Pickup, H. Player, H. Price, A. Stevens, S. Stratton, and J. Wiseman, Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 14 (2004), pp. 5445–5448.
   PubMed Web of Science ®Google Scholar
• P.J. Beswick, A.P. Blackaby, C. Bountra, T. Brown, K. Browning, I.B. Campbell, J. Corfield, R.J. Gleave, S.B. Guntrip, R.M. Hall, S. Hindley, P.F. Lambeth, F. Lucas, N. Mathews, A. Naylor, H. Player, H.S. Price, P.J. Sidebottom, N.L. Taylor, G. Webb, and J. Wiseman, Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach, Bioorg. Med. Chem. Lett. 19 (2009), pp. 4509–4514.
   Google Scholar
• N. Bézière, L. Goossens, J. Pommery, H. Vezin, N. Touati, J.P. Hénichart, and N. Pommery, New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines, Bioorg. Med. Chem. Lett. 18 (2008), pp. 4655–4657.
   Google Scholar
• W.C. Black, C. Brideau, C.C. Chan, S. Charleson, W. Cromlish, R. Gordon, E.L. Grimm, G. Hughes, S. Leger, C.S. Li, D. Riendeau, M. Thérien, Z. Wang, L.J. Xu, and P. Prasit, 3,4-Diaryl-5-hydroxyfuranones: Highly selective inhibitors of cyclooxygenase-2 with aqueous solubility, Bioorg. Med. Chem. Lett. 13 (2003), pp. 1195–1198.
   PubMed Web of Science ®Google Scholar
• A.L. Blobaum and L.J. Marnett, Structural and functional basis of cyclooxygenase inhibition, J. Med. Chem. 50 (2007), pp. 1425–1441.
   Web of Science ®Google Scholar
• S. Boonphong, P. Puangsombat, A. Baramee, C. Mahidol, S. Ruchirawat, and P. Kittakoop, Bioactive compounds from Bauhinia purpurea possessing antimalarial, antimycobacterial, antifungal, anti-inflammatory, and cytotoxic activities, J. Nat. Prod. 70 (2007), pp. 795–801.
   PubMed Web of Science ®Google Scholar
• A. Bridoux, R. Millet, J. Pommery, N. Pommery, and J.-P. Henichart, Synthesis and biological activity of N-aroyl-tetrahydro-γ-carbolines, Bioorg. Med. Chem. 18 (2010), pp. 3910–3924.
   Web of Science ®Google Scholar
• B. Calışkan, S. Luderer, Y. Özkan, O. Werz, and E. Banoglu, Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils, Eur. J. Med. Chem. 46 (2011), pp. 5021–5033.
   Web of Science ®Google Scholar
• J.A. Campbell, V. Bordunov, C.A. Broka, M.F. Browner, J.M. Kress, T. Mirzadegan, C. Ramesha, B.F. Sanpablo, R. Stabler, P. Takahara, A. Villasenor, K.A.M. Walker, J.-H. Wang, M. Welch, and P. Weller, Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 14 (2004), pp. 4741–4745.
   PubMed Web of Science ®Google Scholar
• J.S. Carter, S. Kramer, J.J. Talley, T. Penning, P. Collins, M.J. Graneto, K. Seibert, C.M. Koboldt, J. Masferrer, and B. Zweifel, Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999), pp. 1171–1174.
   PubMed Web of Science ®Google Scholar
• J.S. Carter, D.J. Rogier, M.J. Graneto, K. Seibert, C.M. Koboldt, Y. Zhang, J.J. Talley, C.P. North, and S. Louis, Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999), pp. 1167–1170.
   PubMed Web of Science ®Google Scholar
• F. Caturla, J.-M. Jiménez, N. Godessart, M. Amat, A. Cárdenas, L. Soca, J. Beleta, H. Ryder, and M.I. Crespo, Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors, J. Med. Chem. 47 (2004), pp. 3874–3886.
   Google Scholar
• K. Chegaev, L. Lazzarato, P. Tosco, C. Cena, E. Marini, B. Rolando, P.A. Carrupt, R. Fruttero, and A. Gasco, NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties, J. Med. Chem. 50 (2007), pp. 1449–1457.
   Google Scholar
• Z. Chen, Y. Wu, Y. Liu, S. Yang, Y. Chen, and L. Lai, Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4hydrolyase, J. Med. Chem. 54 (2011), pp. 3650–3660.
   Web of Science ®Google Scholar
• Z. Chen, Z.-C. Wang, X.-Q. Yan, P.-F. Wang, X.-Y. Lu, L.-W. Chen, H.-L. Zhu, and H.-W. Zhang, Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors, Bioorg. Med. Chem. Lett. 25 (2015), pp. 1947–1951.
   PubMed Web of Science ®Google Scholar
• A. Crespo, C. Meyers, A. Coelho, M. Yáñez, N. Fraiz, E. Sotelo, B.U.W. Maes, R. Laguna, E. Cano, G.L.F. Lemière, and E. Raviña, Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl) pyridazin-3(2H)-ones, Bioorg. Med. Chem. Lett. 16 (2006), pp. 1080–1083.
   PubMed Web of Science ®Google Scholar
• R.W. Friesen, D. Dubé, R. Fortin, R. Frenette, S. Prescott, W. Cromlish, G.M. Greig, S. Kargman, E. Wong, C.C. Chan, R. Gordon, L.J. Xu, and D. Riendeau, Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors, Bioorg. Med. Chem. Lett. 6 (1996), pp. 2677–2682.
   Web of Science ®Google Scholar
• R.W. Friesen, C. Brideau, C.C. Chan, S. Charleson, D. Deschanes, D. Dub, D. Ethier, R. Fortin, J.Y. Gauthier, Y. Girard, R. Gordon, G.M. Greig, D. Riendeau, C. Savoie, Z. Wang, E. Wong, D. Visco, L.J. Xu, and R.N. Young, 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines, Bioorg. Med. Chem. Lett. 8 (1998), pp. 2777–2782.
   PubMed Web of Science ®Google Scholar
• R. Gautam, S.M. Jachak, V. Kumar, and C.G. Mohan, Synthesis, biological evaluation and molecular docking studies of stellatin derivatives as cyclooxygenase (COX-1, COX-2) inhibitors and anti-inflammatory agents, Bioorg. Med. Chem. Lett. 21 (2011), pp. 1612–1616.
   PubMed Web of Science ®Google Scholar
• J.Y. Gauthier, R. Gordon, G. Greig, J. Guay, S. Kargman, C.K. Lau, G.O. Neill, J. Silva, C. Van Staden, E. Wong, L. Xu, and P. Prasit, A new series of selective COX-2 inhibitors: 5,6-Diarylthiazolo[3,2-b][1,2,4]triazoles, Bioorg. Med. Chem. Lett. 7 (1997), pp. 57–62.
   Web of Science ®Google Scholar
• J.Y. Gauthier, Y. Leblanc, W.C. Black, C.C. Chan, W.A. Cromlish, R. Gordon, B.P. Kennedey, C.K. Lau, S. Léger, Z. Wang, D. Ethier, J. Guay, J. Mancini, D. Riendeau, P. Tagari, P. Vickers, E. Wong, L. Xu, and P. Prasit, Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 inhibitors. Part II: Replacing the heterocycle, Bioorg. Med. Chem. Lett. 6 (1996), pp. 87–92.
   Google Scholar
• A.G. Habeeb, P.N.P. Rao, and E.E. Knaus, Design and synthesis of 4,5-diphenyl-4-isoxazolines: Novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity, J. Med. Chem. 44 (2001), pp. 2921–2927.
   Web of Science ®Google Scholar
• Y. Harrak, G. Rosell, G. Daidone, S. Plescia, D. Schillaci, and M.D. Pujol, Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system, Bioorg. Med. Chem. 15 (2007), pp. 4876–4890.
   Web of Science ®Google Scholar
• H. Hashimoto, K. Imamura, J. Haruta, and K. Wakitani, 4-(4-Cycloalkyl/aryl-oxazol-5-yl) benzenesulfonamides as selective cyclooxygenase-2 inhibitors: Enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522, J. Med. Chem. 45 (2002), pp. 1511–1517.
   Web of Science ®Google Scholar
• H. Hashimoto, K. Maeda, K. Ozawa, and J. Haruta, 4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors, Bioorg. Med. Chem. Lett. 12 (2002), pp. 65–68.
   PubMed Web of Science ®Google Scholar
• S. Hayashi, N. Ueno, A. Murase, Y. Nakagawa, and J. Takada, Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure–activity relationship for anti-inflammatory drug, Eur. J. Med. Chem. 50 (2012), pp. 179–195.
   Web of Science ®Google Scholar
• H.C. Huang, J.J. Li, D.J. Garland, T.S. Chamberlain, E.J. Reinhard, R.E. Manning, K. Seibert, C.M. Koboldt, S.A. Gregory, G.D. Anderson, A.W. Veenhuizen, Y. Zhang, W.E. Perkins, E.G. Burton, J.N. Cogburn, P.C. Isakson, and D.B. Reitz, Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure–activity relationships, J. Med. Chem. 39 (1996), pp. 253–266.
   Google Scholar
• H.C. Huang, T.S. Chamberlain, K. Selbert, C.M. Koboldt, P.C. Isakson, and D.B. Reitz, Diaryl indenes and benzofurans: Novel classes of potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 5 (1995), pp. 2377–2380.
   Google Scholar
• J.M. Janusz, P.A. Young, J.M. Ridgeway, M.W. Scherz, K. Enzweiler, L.I. Wu, L. Gan, J. Chen, D.E. Kellstein, S.A. Green, J.L. Tulich, T. Rosario-Jansen, I.J. Magrisso, K.R. Wehmeyer, D.L. Kuhlenbeck, T.H. Eichhold, and R.L.M. Dobson, New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-Butyl-2,3- dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations at the 5 position, J. Med. Chem. 41 (1998), pp. 3515–3529.
   Google Scholar
• J.M. Janusz, P.A. Young, J.M. Ridgeway, M.W. Scherz, K. Enzweiler, L.I. Wu, L. Gan, R. Darolia, R.S. Matthews, D. Hennes, D.E. Kellstein, S.A. Green, J.L. Tulich, T. Rosario-Jansen, I.J. Magrisso, K.R. Wehmeyer, D.L. Kuhlenbeck, T.H. Eichhold, R.L.M. Dobson, S.P. Sirko, and R.W. Farmer, New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzonfuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Discovery and variation of the 5-keto substituent, J. Med. Chem. 41 (1998), pp. 1112–1123.
   Google Scholar
• J.M. Janusz, P.A. Young, M.W. Scherz, K. Enzweiler, L.I. Wu, L. Gan, S. Pikul, K.L. McDow-Dunham, C.R. Johnson, C.B. Senanayake, D.E. Kellstein, S.A. Green, J.L. Tulich, T. Rosario-Jansen, I.J. Magrisso, K.R. Wehmeyer, D.L. Kuhlenbeck, T.H. Eichhold, and R.L.M. Dobson, New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations of the dihydrobenzofuran ring, J. Med. Chem. 41 (1998), pp. 1124–1137.
   Google Scholar
• S.S. Kang, M. Cuendet, D.C. Endringer, V.L. Croy, J.M. Pezzuto, and M.A. Lipton, Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-κB, Bioorg. Med. Chem. 17 (2009), pp. 1044–1054.
   Google Scholar
• K.M. Khan, N. Ambreen, U.R. Mughal, S. Jalil, S. Perveen, and M.I. Choudhary, 3-Formylchromones: Potential antiinflammatory agents, Eur. J. Med. Chem. 45 (2010), pp. 4058–4064.
   Google Scholar
• I.K. Khanna, R.M. Weier, Y. Yu, P.W. Collins, J.M. Miyashiro, C.M. Koboldt, A.W. Veenhuizen, J.L. Currie, K. Seibert, and P.C. Isakson, 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2, J. Med. Chem. 40 (1997), pp. 1619–1633.
   Web of Science ®Google Scholar
• I.K. Khanna, R.M. Weier, Y. Yu, X.D. Xu, F.J. Koszyk, P.W. Collins, C.M. Koboldt, A.W. Veenhuizen, W.E. Perkins, J.J. Casier, J.L. Masferrer, Y.Y. Zhang, S.A. Gregory, K. Seibert, and P.C. Isakson, 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents, J. Med. Chem. 40 (1997), pp. 1634–1647.
   Google Scholar
• I.K. Khanna, Y. Yu, R.M. Huff, R.M. Weier, X. Xu, F.J. Koszyk, P.W. Collins, J.N. Cogburn, P.C. Isakson, C.M. Koboldt, J.L. Masferrer, W.E. Perkins, K. Seibert, A.W. Veenhuizen, J. Yuan, D. Yang, and Y.Y. Zhang, Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents, J. Med. Chem. 43 (2000), pp. 3168–3185.
   Web of Science ®Google Scholar
• C.K. Lau, C. Brideau, C.C. Chan, S. Charleson, W.A. Cromlish, D. Ethier, Y. Gauthier, R. Gordon, J. Guay, S. Kargman, C. Li, P. Prasit, D. Riendeau, M. Thrien, D.M. Visco, and L. Xu, Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors, Bioorg. Med. Chem. Lett. 9 (1999), pp. 3187–3192.
   PubMed Web of Science ®Google Scholar
• E.S. Lazer, C.K. Miao, C.L. Cywin, R. Sorcek, H.C. Wong, Z. Meng, I. Potocki, M.A. Hoermann, R.J. Snow, M.A. Tschantz, T.A. Kelly, D.W. McNeil, S.J. Coutts, L. Churchill, A.G. Graham, E. David, P.M. Grob, W. Engel, H. Meier, and G. Trummlitz, Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity, J. Med. Chem. 40 (1997), pp. 980–989.
   Web of Science ®Google Scholar
• E.S. Lazer, R. Sorcek, C.L. Cywin, D. Thome, G.J. Possanza, and A.G. Graham, Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: Novel inhibitors of COX-2, Bioorg. Med. Chem. Lett. 8 (1998), pp. 1181–1186.
   PubMed Web of Science ®Google Scholar
• Y. Leblanc, J. Gauthier, D. Ethier, J. Guay, J. Mancini, D. Riendeau, P. Tagari, P. Vickers, E. Wong, and P. Prasit, Synthesis and biological evaluation of 2, 3-diarylthiophenes as selective COX-2 and COX-1 inhibitors, Bioorg. Med. Chem. Lett. 5 (1995), pp. 2123–2128.
   Web of Science ®Google Scholar
• C.S. Li, C. Brideau, C.C. Chan, C. Savoie, D. Claveau, S. Charleson, R. Gordon, G. Greig, J.Y. Gauthier, C.K. Lau, E. Wong, P. Prasit, D. Riendeau, and M. The, Pyridazinones as selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 13 (2003), pp. 597–600.
   PubMed Web of Science ®Google Scholar
• C.-S. Li, W.C. Black, C.-C. Chan, A.W. Ford-Hutchinson, J.-Y. Gauthier, R. Gordon, D. Guay, S. Kargman, and C.K. Lau, Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives, J. Med. Chem. 38 (1995), pp. 4897–4905.
   Google Scholar
• J.J. Li, G.D. Anderson, E.G. Burton, J.N. Cogburn, J.T. Collins, D.J. Garland, S.A. Gregory, H.C. Huang, P.C. Isakson, and C.M. Koboldt, 1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents, J. Med. Chem. 38 (1995), pp. 4570–4578.
   Web of Science ®Google Scholar
• J.J. Li, M.B. Norton, E.J. Reinhard, G.D. Anderson, S.A. Gregory, P.C. Isakson, C.M. Koboldt, J.L. Masferrer, W.E. Perkins, K. Seibert, Y. Zhang, B.S. Zweifel, and D.B. Reitz, Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents, J. Med. Chem. 39 (1996), pp. 1846–1856.
   Web of Science ®Google Scholar
• A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, and T.M. Penning, Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer, J. Med. Chem. 56 (2013), pp. 2429–2446.
   Web of Science ®Google Scholar
• G.C. Look, J.R. Schullek, C.P. Holmes, J.P. Chinn, E.M. Gordon, and M.A. Gallop, The identification of cyclooxygenase-i inhibitors from 4-thiazolidinone combinatorial libraries, Bioorg. Med. Chem. Lett. 6 (1996), pp. 707–712.
   Web of Science ®Google Scholar
• X. Lu, H. Zhang, X. Li, G. Chen, Q.S. Li, Y. Luo, B.F. Ruan, X.W. Chen, and H.L. Zhu, Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors, Bioorg. Med. Chem. 19 (2011), pp. 6827–6832.
   Google Scholar
• D.A. Nicoll-Griffith, J.A. Yergey, L.A. Trimble, J.M. Silva, C. Li, N. Chauret, J.Y. Gauthier, E. Grimm, S. Léger, P. Roy, M. Thérien, Z. Wang, P. Prasit, R. Zamboni, R.N. Young, C. Brideau, C.C. Chan, J. Mancini, and D. Riendeau, Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™), Bioorg. Med. Chem. Lett. 10 (2000), pp. 2683–2686.
   PubMed Web of Science ®Google Scholar
• L. Di Nunno, P. Vitale, A. Scilimati, S. Tacconelli, and P. Patrignani, Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: Reversal cyclooxygenase-2 selectivity by sulfonamide group removal, J. Med. Chem. 47 (2004), pp. 4881–4890.
   Web of Science ®Google Scholar
• N. Ouimet, C.C. Chan, S. Charleson, D. Claveau, R. Gordon, D. Guay, L. Chun-Sing, M. Ouellet, D.M. Percival, D. Riendeau, E. Wong, R. Zamboni, and P. Prasit, Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class, Bioorg. Med. Chem. Lett. 9 (1999), pp. 151–156.
   PubMed Web of Science ®Google Scholar
• M. Pal, V. Rao Veeramaneni, M. Nagabelli, S. Rao Kalleda, P. Misra, S. Rao Casturi, and K. Rao Yeleswarapu, Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 13 (2003), pp. 1639–1643.
   PubMed Web of Science ®Google Scholar
• A. Palomer, J. Pascual, M. Cabré, L. Borràs, G. González, M. Aparici, A. Carabaza, F. Cabré, M.L. García, and D. Mauleón, Structure-based design of cyclooxygenase-2 selectivity into ketoprofen, Bioorg. Med. Chem. Lett. 12 (2002), pp. 533–537.
   PubMed Web of Science ®Google Scholar
• R. Paramashivappa, P. Phani Kumar, P.V. Subba Rao, and A. Srinivasa Rao, Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors, Bioorg. Med. Chem. Lett. 13 (2003), pp. 657–660.
   PubMed Web of Science ®Google Scholar
• T.D. Penning, J.J. Talley, S.R. Bertenshaw, J.S. Carter, P.W. Collins, S. Docter, M.J. Graneto, L.F. Lee, J.W. Malecha, J.M. Miyashiro, R.S. Rogers, D.J. Rogier, S.S. Yu, G.D. Anderson, E.G. Burton, J.N. Cogburn, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang, and P.C. Isakson, Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib), J. Med. Chem. 40 (1997), pp. 1347–1365.
   Web of Science ®Google Scholar
• T.D. Penning, S.W. Kramer, L.F. Lee, P.W. Collins, C.M. Koboldt, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang, and P.C. Isakson, 3,4-diarylpyrazoles: Potent and selective inhibitors of cyclooxygenase-2, Bioorg. Med. Chem. Lett. 7 (1997), pp. 2121–2124.
   Web of Science ®Google Scholar
• N. Pommery, T. Taverne, L. Goossens, C. Charlier, and J. Pommery, New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy, J. Med. Chem. 47 (2004), pp. 6195–6206.
   Web of Science ®Google Scholar
• P. Prasit, Z. Wang, C. Brideau, C.C. Chan, S. Charleson, W. Cromlish, D. Ethier, J.F. Evans, A.W. Ford-Hutchinson, J.Y. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, B. Kennedy, Y. Leblanc, S. Léger, J. Mancini, G.P. O’Neill, M. Ouellet, M.D. Percival, H. Perrier, D. Riendeau, I. Rodger, and R. Zamboni, The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor, Bioorg. Med. Chem. Lett. 9 (1999), pp. 1773–1778.
   PubMed Web of Science ®Google Scholar
• C. Puig, M.I. Crespo, N. Godessart, J. Feixas, J. Ibarzo, J.M. Jiménez, L. Soca, I. Cardelús, A. Heredia, M. Miralpeix, J. Puig, J. Beleta, J.M. Huerta, M. López, V. Segarra, H. Ryder, and J.M. Palacios, Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors, J. Med. Chem. 43 (2000), pp. 214–223.
   Google Scholar
• K.-M. Qiu, R. Yan, M. Xing, H.-H. Wang, H.-E. Cui, H.-B. Gong, and H.-L. Zhu, Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors, Bioorg. Med. Chem. 20 (2012), pp. 6648–6654.
   Google Scholar
• D.B. Reitz, J.J. Li, M.B. Norton, E.J. Reinhard, J.T. Collins, G.D. Anderson, S.A. Gregory, C.M. Koboldt, W.E. Perkins, and K. Seibert, Selective cyclooxygenase inhibitors: Novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors, J. Med. Chem. 37 (1994), pp. 3878–3881.
   Web of Science ®Google Scholar
• D.B. Reitz, H. Huang, J.J. Li, D.J. Garland, R.E. Manning, G.D. Anderson, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, and P.C. Isakson, Selective cyclooxygenase inhibitors: Novel 4-spiro 1,2-diarylcyclopentenes are potent and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 5 (1995), pp. 867–872.
   Web of Science ®Google Scholar
• J.F. Renard, F. Lecomte, P. Hubert, X. De Leval, and B. Pirotte, N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: Cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism, Eur. J. Med. Chem. 74 (2014), pp. 12–22.
   Web of Science ®Google Scholar
• M. Resch, A. Steigel, Z.L. Chen, and R. Bauer, 5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from Atractylodes lancea, J. Nat. Prod. 61 (1998), pp. 347–350.
   PubMed Web of Science ®Google Scholar
• D. Riendeau, M. Salem, A. Styhler, M. Ouellet, J.A. Mancini, and C.S. Li, Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2, Bioorg. Med. Chem. Lett. 14 (2004), pp. 1201–1203.
   PubMed Web of Science ®Google Scholar
• P. Singh, A. Mittal, S. Kaur, and S. Kumar, 2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols, Eur. J. Med. Chem. 43 (2008), pp. 2792–2799.
   Web of Science ®Google Scholar
• Y. Song, D.T. Connor, R. Doubleday, R.J. Sorenson, A.D. Sercel, P.C. Unangst, B.D. Roth, R.B. Gilbertsen, K. Chan, D.J. Schrier, A. Guglietta, D.A. Bornemeier, and R.D. Dyer, Synthesis, structure–activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series, J. Med. Chem. 42 (1999), pp. 1151–1160.
   Google Scholar
• Y. Song, D.T. Connor, R. Doubleday, R.J. Sorenson, A.D. Sercel, P.C. Unangst, B.D. Roth, R.B. Gilbertsen, K. Chan, D.J. Schrier, A. Guglietta, D.A. Bornemeier, R.D. Dyer, and V.G. Beylin, Synthesis, structure–activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-Thiadiazole series 1, J. Med. Chem. 42 (1999), pp. 1161–1169.
   Google Scholar
• V. Srinivas, C.D. Mohan, C.P. Baburajeev, S. Rangappa, S. Jagadish, J.E. Fuchs, A.Y. Sukhorukov, Chandra, D.J. Mason, K.S. Sharath Kumar, M. Madegowda, A. Bender, Basappa, and K.S. Rangappa, Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2, Bioorg. Med. Chem. Lett. 25 (2015), pp. 2931–2936.
   Google Scholar
• N.S. Stock, G. Bain, J. Zunic, Y. Li, J. Ziff, J. Roppe, A. Santini, J. Darlington, P. Prodanovich, C.D. King, C. Baccei, C. Lee, H. Rong, C. Chapman, A. Broadhead, D. Lorrain, L. Correa, J.H. Hutchinson, J.F. Evans, and P. Prasit, 5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor, J. Med. Chem. 54 (2011), pp. 8013–8029.
   Google Scholar
• B. Su, M. Cuendet, M.E. Hawthorne, L.B.S. Kardono, S. Riswan, H.H.S. Fong, R.G. Mehta, J.M. Pezzuto, and A.D. Kinghorn, Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity, J. Nat. Prod. 65 (2002), pp. 163–169.
   PubMed Web of Science ®Google Scholar
• Y. Suh, Y. Kim, M. Park, Y. Choi, H. Lee, J. Moon, K. Min, D. Shin, J. Jung, O. Park, R. Jeon, H. Park, and S. Kang, Pimarane cyclooxygenase 2 (COX-2) inhibitor and its structure–activity relationship, Bioorg. Med. Chem. Lett. 11 (2001), pp. 559–562.
   PubMed Web of Science ®Google Scholar
• Z. Sui, J. Guan, M.P. Ferro, K. McCoy, M.P. Wachter, W.V. Murray, M. Singer, M. Steber, D.M. Ritchie, and D.C. Argentieri, 1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxygenase-2, Bioorg. Med. Chem. Lett. 10 (2000), pp. 601–604.
   PubMed Web of Science ®Google Scholar
• M.E. Swarbrick, P.J. Beswick, R.J. Gleave, R.H. Green, S. Bingham, C. Bountra, M.C. Carter, L.J. Chambers, I.P. Chessell, N.M. Clayton, S.D. Collins, J.A. Corfield, C.D. Hartley, S. Kleanthous, P.F. Lambeth, F.S. Lucas, N. Mathews, A. Naylor, L.W. Page, J.J. Payne, N.A. Pegg, H.S. Price, J. Skidmore, A.J. Stevens, R. Stocker, S.C. Stratton, A.J. Stuart, and J.O. Wiseman, Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 4504–4508.
   PubMed Web of Science ®Google Scholar
• T. Takahashi and M. Miyazawa, N-Caffeoyl serotonin as selective COX-2 inhibitor, Bioorg. Med. Chem. Lett. 22 (2012), pp. 2494–2496.
   PubMed Web of Science ®Google Scholar
• M. Thérien, C. Brideau, C.C. Chan, W.A. Cromlish, J.Y. Gauthier, R. Gordon, G. Greig, S. Kargman, C.K. Lau, Y. Leblanc, C. Li, G.P. O’Neill, D. Riendeau, P. Roy, Z. Wang, L. Xu, and P. Prasit, Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors, Bioorg. Med. Chem. Lett. 7 (1997), pp. 47–52.
   Google Scholar
• M.J. Uddin, A.V Elleman, K. Ghebreselasie, C.K. Daniel, B.C. Crews, K.D. Nance, T. Huda, and L.J. Marnett, Design of fluorine-containing 3,4-diarylfuran-2(5H)-ones as selective COX-1 inhibitors, ACS Med. Chem. Lett. 5 (2014), pp. 1254–1258.
   Web of Science ®Google Scholar
• P. Vitale, S. Tacconelli, M.G. Perrone, P. Malerba, L. Simone, A. Scilimati, A. Lavecchia, M. Dovizio, E. Marcantoni, A. Bruno, and P. Patrignani, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase‑1 (COX-1) inhibitors, J. Med. Chem. 1 (2013), pp. 4277–4299.
   Google Scholar
• J.L. Wang, K. Aston, D. Limburg, C. Ludwig, A.E. Hallinan, F. Koszyk, B. Hamper, D. Brown, M. Graneto, J. Talley, T. Maziasz, J. Masferrer, and J. Carter, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates, Bioorg. Med. Chem. Lett. 20 (2010), pp. 7164–7168.
   Google Scholar
• J.L. Wang, J. Carter, J.R. Kiefer, R.G. Kurumbail, J.L. Pawlitz, D. Brown, S.J. Hartmann, M.J. Graneto, K. Seibert, and J.J. Talley, The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate, Bioorg. Med. Chem. Lett. 20 (2010), pp. 7155–7158.
   PubMed Web of Science ®Google Scholar
• J.L. Wang, D. Limburg, M.J. Graneto, J. Springer, J.R.B. Hamper, S. Liao, J.L. Pawlitz, R.G. Kurumbail, T. Maziasz, J.J. Talley, J.R. Kiefer, and J. Carter, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life, Bioorg. Med. Chem. Lett. 20 (2010), pp. 7159–7163.
   Google Scholar
• S.-J. Wey, M.E. Augustyniak, E.D. Cochran, J.L. Ellis, X. Fang, D.S. Garvey, D.R. Janero, L.G. Letts, A.M. Martino, T.L. Melim, M.G. Murty, S.K. Richardson, J.D. Schroeder, W.M. Selig, A.M. Trocha, R.S. Wexler, D.V Young, I.S. Zemtseva, and B.M. Zifcak, Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors, J. Med. Chem. 50 (2007), pp. 6367–6382.
   Web of Science ®Google Scholar
• F. Wuest, X. Tang, T. Kniess, J. Pietzsch, and M. Suresh, Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives, Bioorg. Med. Chem. 17 (2009), pp. 1146–1151.
   Web of Science ®Google Scholar
• L. Xing, B.C. Hamper, T.R. Fletcher, J.M. Wendling, J. Carter, J.K. Gierse, and S. Liao, Structure-based parallel medicinal chemistry approach to improve metabolic stability of benzopyran COX-2 inhibitors, Bioorg. Med. Chem. Lett. 21 (2011), pp. 993–996.
   PubMedGoogle Scholar
• N. Yamakawa, S. Suemasu, M. Matoyama, A. Kimoto, M. Takeda, K.I. Tanaka, T. Ishihara, T. Katsu, Y. Okamoto, M. Otsuka, and T. Mizushima, Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl) methyl]phenyl}propanoic acid: Nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities, J. Med. Chem. 53 (2010), pp. 7879–7882.
   Web of Science ®Google Scholar
• N. Yamakawa, S. Suemasu, M. Matoyama, K.I. Tanaka, T. Katsu, K. Miyata, Y. Okamoto, M. Otsuka, and T. Mizushima, Synthesis and biological evaluation of loxoprofen derivatives, Bioorg. Med. Chem. 19 (2011), pp. 3299–3311.
   Google Scholar
• N. Yamakawa, S. Suemasu, Y. Okamoto, K.I. Tanaka, T. Ishihara, T. Asano, K. Miyata, M. Otsuka, and T. Mizushima, Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: Nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity, J. Med. Chem. 55 (2012), pp. 5143–5150.
   Web of Science ®Google Scholar
• R.-S. Yao, X.-Q. Lu, Q.-X. Guan, L. Zheng, X. Lu, and B.-F. Ruan, Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents, Eur. J. Med. Chem. 62 (2013), pp. 222–231.
   Web of Science ®Google Scholar
• M. Yu, H. Yang, K. Wu, Y. Ji, L. Ju, and X. Lu, Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma, Bioorg. Med. Chem. 22 (2014), pp. 4109–4118.
   Web of Science ®Google Scholar
• Y. Zhang, M.D. Tortorella, Y. Wang, J. Liu, Z. Tu, X. Liu, Y. Bai, D. Wen, X. Lu, Y. Lu, and J.J. Talley, Synthesis of deuterated benzopyran derivatives as selective COX-2 inhibitors with improved pharmacokinetic properties, ACS Med. Chem. Lett. 5 (2014), pp. 1162–1166.
   Web of Science ®Google Scholar
• T. Kohonen, Self-organized formation of topologically correct feature maps, Biol. Cybern. 43 (1982), pp. 59–69.
   Web of Science ®Google Scholar
• SONNIA 4.2. Molecular Networks GmbH, Nuremberg, Germany, 2016; software available at https://www.mn-am.com.
   Google Scholar
• B.D. Christie, D.R. Henry, W.T. Wipke, and T.E. Moock, Database structure and searching in MACCS-3D, Tetrahedron Comput. Meth. 3 (1990), pp. 653–664.
   Google Scholar
• RDKit 2018.03.1: Open-Source Cheminformatics Software, San Francisco, California, USA, 2018 software available at http://www.rdkit.org.
   Google Scholar
• E. Frank, M.A. Hall, and I.H. Witten, The WEKA Workbench, Morgan Kaufmann, Massachusetts, USA, 2016.
   Google Scholar
• Weka 3.8.1; Machine Learning Group at the University of Waikato, Hamilton, New Zealand, 2018, software available at https://www.cs.waikato.ac.nz/~ml/weka.
   Google Scholar
• CORINA Symphony, 3D Structure Generator CORINA 1.0; developed and distributed by Molecular Networks GmbH, Nuremberg, Germany, 2017; software available at https://www.mn-am.com/products/corinasymphony.
   Google Scholar
• L. Breiman, J.H. Friedman, R.A. Olshen, and C.J. Stone, Classification and Regression Trees, Wadsworth, Belmont, CA,1984.
   Google Scholar
• L. Breiman, Random forests, Mach. Learn. 45 (2001), pp. 5–32.
   Google Scholar
• F. Pedregosa, G. Varoquaux, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, and V. Dubourg, Scikit-learn: Machine learning in Python. J. Mach. Learn. Res. 12 (2011), pp, 2825-2830.
   Google Scholar
• J. Gasteiger and C. Jochum, An algorithm for the perception of synthetically important rings, J. Chem. Inf. Comput. Sci. 19 (1979), pp. 43–48.
   Google Scholar